SMFS
ALNY icon

Squar Milner Financial Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Squar Milner Financial Services’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100
Closed -$7K – 819
2018
Q4 		$7K Hold
100
– – 0.01% 517
2018
Q3 		$9K Hold
100
– – 0.01% 510
2018
Q2 		$10K Buy
+100
New +$9.92K 0.01% 572

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Squar Milner Financial Services's ALNY Position: Q1 2019 in Review

Squar Milner Financial Services sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 100 shares — an estimated $7K sold.

Squar Milner Financial Services first reported a position in ALNY in Q2 2018 and held it in 3 quarters. The position peaked at $10K in Q2 2018. 291 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • Squar Milner Financial Services reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Squar Milner Financial Services sold 100 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $7K.
  • Squar Milner Financial Services first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 3 quarters.
  • Squar Milner Financial Services's Alnylam Pharmaceuticals position peaked at $10K in Q2 2018.
  • 291 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Squar Milner Financial Services's 13F filing for Q1 2019, filed 25 Apr 2019.